抗哮喘类药物市场分析和研发进展

摘要

Bronchial asthma is a kind of chronic respiratory disease and its incidence in China is increasing. The clinical use, situation and market data of asthma drugs were analyzed. It is showed that the market size had been steadily enlarging at higher speed and inhaled medication was the main dosage form for asthma drugs. The sales of branded products by multinational corporation were in a leading position in this category. Their subsequent products will be more and more trended to the local administration and to be developed in the direction of suppressing an asthma attack. There are some products at different development stage in GSK, AstraZeneca and Roche companies. Domestic manufacturers should speed up the technical update for the production of asthma drugs.%本文通过对我国临床用抗哮喘药物的市场数据分析，认为其市场规模持续较高增长，吸入用药为抗哮喘药物的主流剂型，跨国公司的原研产品用药金额在该品类中遥遥领先。研发进展剖析出后续产品将更多地向局部用药和多环节抑制哮喘发作方向发展。葛兰素史克、阿斯利康和罗氏在上述亚类中都有产品处于研发阶段，国内厂家需加快上述产品的技术更新。